Blurbs

Analysts’ Top Healthcare Picks: Ibio (IBIO), Larimar Therapeutics (LRMR)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ibio (IBIOResearch Report), Larimar Therapeutics (LRMRResearch Report) and Taysha Gene Therapies (TSHAResearch Report) with bullish sentiments.

Ibio (IBIO)

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Ibio today and set a price target of $1.50. The company’s shares closed last Monday at $0.39, close to its 52-week low of $0.37.

According to TipRanks.com, Buchanan has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -13.5% and a 32.1% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Arbutus Biopharma, and Hookipa Pharma.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ibio with a $1.50 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Larimar Therapeutics (LRMR)

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Larimar Therapeutics today and set a price target of $8.00. The company’s shares closed last Monday at $8.37, close to its 52-week low of $7.00.

According to TipRanks.com, Wolleben has 0 stars on 0-5 stars ranking scale with an average return of -15.9% and a 30.1% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Crinetics Pharmaceuticals, and Madrigal Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Larimar Therapeutics with a $8.00 average price target.

Taysha Gene Therapies (TSHA)

JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Taysha Gene Therapies today and set a price target of $44.00. The company’s shares closed last Monday at $7.35, close to its 52-week low of $6.57.

According to TipRanks.com, Tuerkcan is a 3-star analyst with an average return of 6.0% and a 33.3% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Crispr Therapeutics AG, and Logicbio Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Taysha Gene Therapies with a $44.00 average price target, representing a 493.8% upside. In a report issued on January 31, Jefferies also maintained a Buy rating on the stock with a $41.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on IBIO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos